Knight Therapeutics (TSE:GUD) Announces Earnings Results

Knight Therapeutics (TSE:GUD) posted its quarterly earnings data on Thursday. The company reported C$0.13 EPS for the quarter, FiscalAI reports. Knight Therapeutics had a net margin of 1.10% and a return on equity of 0.73%. The company had revenue of C$147.59 million for the quarter.

Here are the key takeaways from Knight Therapeutics’ conference call:

• Reported record Q1 results with CAD 148 million in revenues (≈69% YoY growth) and CAD 28 million adjusted EBITDA (≈130% YoY), driven by acquired portfolios and promoted products.
• Raised 2026 guidance to CAD 510–525 million in revenues and targeted adjusted EBITDA of ~15% of revenues, citing stronger promoted-product performance and improved LatAm FX.
• Pipeline and commercialization momentum: regulatory submissions for Niktimvo (Brazil) and Minjuvi (Argentina, Mexico), Brazilian approval of Minjuvi’s second indication, four launches completed in 2026 so far and management expects roughly ~10 launches in 2026.
• Withdrew the Health Canada NDS for Kalbi due to partner manufacturing changes; resubmission and launch are expected later (management estimated a ~1–2 year delay), deferring near-term Canadian revenue from this product.
• Balance sheet and cash flow strengthened: CAD 127 million in cash/marketable securities, net cash of ~CAD 69 million, CAD 41 million operating cash inflow in Q1, ongoing NCIB purchases and capacity to fund further BD/acquisitions.

Knight Therapeutics Price Performance

GUD opened at C$8.69 on Friday. The company has a fifty day simple moving average of C$7.03 and a 200 day simple moving average of C$6.36. The firm has a market cap of C$852.11 million, a price-to-earnings ratio of -173.80, a PEG ratio of -1,013.50 and a beta of -0.21. Knight Therapeutics has a twelve month low of C$5.65 and a twelve month high of C$8.70. The company has a current ratio of 2.32, a quick ratio of 1.79 and a debt-to-equity ratio of 8.86.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group set a C$9.50 price target on shares of Knight Therapeutics and gave the company a “buy” rating in a research report on Friday. One analyst has rated the stock with a Buy rating, According to MarketBeat.com, Knight Therapeutics currently has a consensus rating of “Buy” and a consensus price target of C$9.50.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.